Eli Lilly Wants to Join Lawsuit Over Compounded Weight-Loss Drugs
The lawsuit was brought against the FDA after the agency declared an end to the shortage that allowed pharmacies to sell compound versions of the popular weight loss drugs, but Eli Lilly said it cannot rely on the FDA to protect it's interests.
Should Pharmaceutical Companies Sell Weight-Loss Drugs Directly to Consumers?
Conversely, Eduardo Grunvald, MD, medical director of the weight management program at UC San Diego Health, sees less of an issue as long as there is a legitimate prescriber. Some of his patients have found it easier to get access to tirzepatide during shortages using LillyDirect.
The Food and Drug Administration approved Eli Lilly’s weight-loss drug Zepbound on Dec. 27 to treat sleep apnea, a common but ...
Here are some clinical trials that could send Big Pharma shares soaring, or crashing, in 2025. Eli Lilly. The world’s biggest ...
Merck will pay Hansoh $112 million upfront for rights to the drug, with the potential for an additional $1.9 billion in ...
In a recent head-to-head study involving Novo Nordisk 's Wegovy, Zepbound came out on top, resulting in average weight loss ...
Eli Lilly’s Zepbound drug holds potential to dominate the global obesity market due to its superior efficacy and strategic ...
Pfizer, AstraZeneca, Amgen and several other drug developers aiming to join the weight-loss drug market, which is estimated ...
Eli Lilly expects to have data from a late-stage trial involving orforglipron by April. This weight loss pill helped patients lose nearly 15% of their weight in a phase 2 trial. Lilly has ...
Novo Nordisk ( NVO) reported its newest GLP-1 product, CagriSema, provides an average of 22.7% weight loss, but that wasn't ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback